// App-Quantinova.ai

11042 : Effect of exemestane plus everolimus on CTC counts and Ki-67 expression on CTCs in patients with advanced hormone receptor-positive, HER2-negative breast cancer.

Researchers

Presenter

  • Sofia Agelaki

Principal Investigators

  • Maria Spiliotaki

  • Athanasios Kotsakis

  • Dimitrios Mavroudis

  • Vassilis Georgoulias

  • Christos Nikolaou

  • Eleni Politaki

  • Stella Apostolaki

Medical Centers

  • Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece

  • Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Greece

Locations

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Peripheral blood mononuclear cell

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Everolimus

  • Exemestane

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved